The United States Patent Office (USPTO) has granted the company patent US titled “Porous silica material for use as a pharmaceutical or dietary active ingredient”. The patent supports use of Sigrid’s mesoporous SiPore silica particles, which consist of precisely engineered micron-sized silica particles with tailored porosity, for lowering blood glucose levels. The patent also supports the use of the mesoporous SiPore silica particles for treating or reducing the risk of developing metabolic syndrome, type-2 diabetes, insulin resistance, or hyperglycaemia. 

“The granting of this patent significantly strengthens Sigrid’s global IP portfolio and highlights the versatility of our SiPore technology in addressing critical metabolic health challenges,” says Ghislaine Robert-Nicoud, Head of Product Development at Sigrid Therapeutics.  

Related article

A treatment shift? Nordic progress beyond GLP-1

In the wake of the groundbreaking GLP-1 receptor agonists, a number of new obesity treatments and weight management approaches are emerging  – and a few of them come from the Nordic region. Behavior Lifestyle changes are critical for weight loss, even for patients taking the GLP-1 anti-obesity drugs, and we all know that implementing and […]


“The recognition of our product’s potential by the USPTO further validates our expertise in developing groundbreaking silica-based biomaterials for managing blood glucose and reducing the risks of diabetes and related conditions. This milestone enhances the commercial appeal of SiPore in one of the most important global markets. It comes as we finalize our SHINE clinical trial in people with elevated blood glucose levels who are living with obesity or excess weight, with results expected in QI 2025,” continues Robert-Nicoud. 

In 2021, the European Patent Office (EPO) similarly granted the company patent EP2916852B1 for the use of porous SiPore silica particles as pharmaceutical or dietary active ingredients. The European patent is validated in key markets including the EU, UK, Switzerland, Norway, Iceland and Turkey.  

This new patent further solidifies our competitive edge as we advance discussions with leading global consumer healthcare companies and top-performing regional distributors, who have shown strong interest in partnering with us upon achieving regulatory approvals.

“Our vision with SiPore 21 is to transform blood sugar control by delivering an accessible and effective solution that enables millions of individuals worldwide to take charge of their metabolic health. This new patent further solidifies our competitive edge as we advance discussions with leading global consumer healthcare companies and top-performing regional distributors, who have shown strong interest in partnering with us upon achieving regulatory approvals,” says Sana Alajmovic, Co-founder & CEO of Sigrid Therapeutics.